Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascending dose randomized phase 1 studies in healthy subjects.
IRAK4
Pharmacodynamic
Pharmacokinetic
Journal
Arthritis research & therapy
ISSN: 1478-6362
Titre abrégé: Arthritis Res Ther
Pays: England
ID NLM: 101154438
Informations de publication
Date de publication:
05 12 2019
05 12 2019
Historique:
received:
07
03
2019
accepted:
23
09
2019
entrez:
7
12
2019
pubmed:
7
12
2019
medline:
10
9
2020
Statut:
epublish
Résumé
PF-06650833 is a potent, selective inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4). Two randomized, double-blind, sponsor-open phase 1 studies evaluated the safety, pharmacokinetics, and pharmacodynamics of single (SAD) and multiple ascending doses (MAD) of PF-06650833 immediate-release (IR) and modified-release (MR) oral formulations in healthy adult subjects. Study 1 (NCT02224651) was a 96-day, placebo-substitution, SAD study of once-daily (QD) oral PF-06650833 IR 1 to 6000 mg and MR 30 to 300 mg in fasted and fed states. Study 2 (NCT02485769) was a 14-day, placebo-controlled, MAD study of PF-06650833 IR 25 to 750 mg twice daily, IR 1000 mg four times per day, IR 330 mg three times per day, and MR 300 mg QD. PF-06650833 was generally well tolerated, with no dose-limiting treatment-emergent adverse events (TEAEs) identified in either study. TEAEs were generally mild in severity, with headache, gastrointestinal disorders, and acne most commonly reported. No serious AEs or deaths were reported. A maximum tolerated dose was not established in either study. In the SAD study, food intake delayed absorption of IR 30 mg and increased total exposure by 33%. Delayed absorption was achieved with the MR formulation (T PF-06650833, the first IRAK4 inhibitor to enter clinical development, has a favorable safety and pharmacokinetic profile and has shown evidence of pharmacological effect. The data support continued evaluation in human clinical trials for the treatment of rheumatic and autoimmune diseases. Clinicaltrials.gov, NCT02224651, registered 25 August 2014; NCT02485769, registered 30 June 2015.
Sections du résumé
BACKGROUND
PF-06650833 is a potent, selective inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4). Two randomized, double-blind, sponsor-open phase 1 studies evaluated the safety, pharmacokinetics, and pharmacodynamics of single (SAD) and multiple ascending doses (MAD) of PF-06650833 immediate-release (IR) and modified-release (MR) oral formulations in healthy adult subjects.
METHODS
Study 1 (NCT02224651) was a 96-day, placebo-substitution, SAD study of once-daily (QD) oral PF-06650833 IR 1 to 6000 mg and MR 30 to 300 mg in fasted and fed states. Study 2 (NCT02485769) was a 14-day, placebo-controlled, MAD study of PF-06650833 IR 25 to 750 mg twice daily, IR 1000 mg four times per day, IR 330 mg three times per day, and MR 300 mg QD.
RESULTS
PF-06650833 was generally well tolerated, with no dose-limiting treatment-emergent adverse events (TEAEs) identified in either study. TEAEs were generally mild in severity, with headache, gastrointestinal disorders, and acne most commonly reported. No serious AEs or deaths were reported. A maximum tolerated dose was not established in either study. In the SAD study, food intake delayed absorption of IR 30 mg and increased total exposure by 33%. Delayed absorption was achieved with the MR formulation (T
CONCLUSIONS
PF-06650833, the first IRAK4 inhibitor to enter clinical development, has a favorable safety and pharmacokinetic profile and has shown evidence of pharmacological effect. The data support continued evaluation in human clinical trials for the treatment of rheumatic and autoimmune diseases.
TRIAL REGISTRATION
Clinicaltrials.gov, NCT02224651, registered 25 August 2014; NCT02485769, registered 30 June 2015.
Identifiants
pubmed: 31805989
doi: 10.1186/s13075-019-2008-6
pii: 10.1186/s13075-019-2008-6
pmc: PMC6896740
doi:
Substances chimiques
Antirheumatic Agents
0
Isoquinolines
0
Lactams
0
IRAK4 protein, human
EC 2.7.11.1
Interleukin-1 Receptor-Associated Kinases
EC 2.7.11.1
1-(((2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6-carboxamide
S3F315JJXI
Banques de données
ClinicalTrials.gov
['NCT02224651', 'NCT02485769']
Types de publication
Clinical Trial, Phase I
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
269Références
Ann Rheum Dis. 2016 Jan;75(1):3-15
pubmed: 25969430
Rheumatology (Oxford). 2017 Nov 1;56(11):1945-1961
pubmed: 28968809
ACS Med Chem Lett. 2015 May 12;6(6):677-82
pubmed: 26101573
Ann Rheum Dis. 2014 Jul;73(7):1316-22
pubmed: 24550173
J Med Chem. 2017 Jul 13;60(13):5521-5542
pubmed: 28498658
Ann Rheum Dis. 2014 Jun;73(6):958-67
pubmed: 24739325
Autoimmun Rev. 2014 Nov;13(11):1114-20
pubmed: 25182207
J Biol Chem. 2017 Nov 10;292(45):18689-18698
pubmed: 28924041
Bioorg Med Chem Lett. 2014 May 1;24(9):2066-72
pubmed: 24726805
Proc Natl Acad Sci U S A. 2009 Jul 21;106(29):12061-6
pubmed: 19574451
Rheumatol Int. 2016 May;36(5):685-95
pubmed: 26746843
Arthritis Rheum. 2008 Sep;58(9):2642-51
pubmed: 18759292
Arthritis Rheum. 2011 Jan;63(1):53-62
pubmed: 20954191
J Exp Med. 2015 Dec 14;212(13):2189-201
pubmed: 26621451
Blood. 2014 Dec 4;124(24):3561-71
pubmed: 25320238
Nature. 2010 Jun 17;465(7300):937-41
pubmed: 20559388
Br J Clin Pharmacol. 2011 Feb;71(2):183-9
pubmed: 21219398
Ann Rheum Dis. 2014 Aug;73(8):1462-9
pubmed: 24590181
Cell Death Differ. 2006 May;13(5):816-25
pubmed: 16410796
Nat Rev Rheumatol. 2014 Sep;10(9):567-71
pubmed: 25048762